A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma

Oncologist

Volumn 10, Issue 6, 2005, Pages 392-398

  Zhu, Andrew X ^a,b   Fuchs, Charles S ^a   Clark, Jeffrey W ^a   Muzikansky, Alona ^a   Taylor, Kerry ^a   Sheehan, Susan ^a   Tam, Kayao ^a   Yung, Elizabeth ^a   Kulke, Matthew H ^a   Ryan, David P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Angiogenesis; Clinical study; Epirubicin; Hepatocellular carcinoma; Thalidomide

Indexed keywords

EPIRUBICIN; THALIDOMID; THALIDOMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE DURATION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; INOPERABLE CANCER; LIVER CELL CARCINOMA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SENSORY NEUROPATHY; SYSTEMIC THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 22244436300     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.10-6-392     Document Type: Article

References (30)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.
3. El-Serag HB, Davila JA, Petersen NJ et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
4. Mathurin P, Rixe O, Carbonell N et al. Review article: overview of medical treatments in unresectable hepatocellular carcinoma-an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-126.
5. Simonetti RG, Liberati A, Angiolini C et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997;8:117-136.
6. Leung TW, Patt YZ, Lau WY et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
7. Yeo W, Zee B, Leung WT et al. A phase III study of doxorubicin (A) versus cisplatin (P)/interferonα-2b (I)/doxorubicin (A)/fluorouracil (F) combination chemotherapy (PIAF) for inoperable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2004;22:4026.
8. Hochster HS, Green MD, Speyer J et al. 4′Epidoxorubicin (epirubicin): activity in hepatocellular carcinoma. J Clin Oncol 1985;3:1535-1540.
9. Dobbs NA, Twelves CJ, Rizzi P et al. Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 1994;34:405-410.
10. Shiu W, Leung N, Li M et al. The efficacy of high-dose 4′epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol 1988;18:235-237.
11. Pohl J, Zuna I, Stremmel W et al. Systemic chemotherapy with epirubicin for treatment of advanced or multifocal hepatocellular carcinoma. Chemotherapy 2001;47:359-365.
12. Joensuu H, Holli K, Heikkinen M et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998;16:3720-3730.
13. Barni S, Archili C, Lissoni P et al. A weekly schedule of epirubicin in pretreated advanced breast cancer. Tumori 1993;79:45-48.
14. Yamaguchi R, Yano H, Iemura A et al. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998;28:68-77.
15. Miura H, Miyazaki T, Kuroda M et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997;27:854-861.
16. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004;57:867-871.
17. Chao Y, Li CP, Chau GY et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003;10:355-362.
18. Poon RT, Ho JW, Tong CS et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004;91:1354-1360.
19. Jeng KS, Sheen IS, Wang YC et al. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol 2004;10:643-648.
20. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
21. Patt YZ, Hassan M, Lozano R. Phase II trial of Thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2000;19:1035.
22. Hsu C, Chen CN, Chen LT et al. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65:242-249.
23. Wang TE, Kao CR, Lin SC et al. Salvage therapy for hepato-cellular carcinoma with thalidomide. World J Gastroenterol 2004;10:649-653.
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
25. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1959;53:457-481.
26. Lin AY, Brophy N, Fisher GA et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005;103:119-125.
27. Patt YZ, Hassan MM, Lozano RD et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005;103:749-755.
28. Carrion Valero F, Bertomeu Gonzalez V. [Lung toxicity due to thalidomide]. Arch Bronconeumol 2002;38:492-494 [Spanish].
29. Schwartz JD, Schwartz M, Goldman J et al. Bevacizumab in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 2005. Abstract 134.
30. Zhu AX, Sahani D, Norden-Zfoni A et al. A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma. American Society of Clinical Oncology Gastrointestinal Cancers Symposium, 2005. January 27-29, 2005. Hollywood, FL. Abstract 131.